Diagnosis and classification of rheumatoid arthritis

Journal of Autoimmunity

Volumn 48-49, Issue , 2014, Pages 26-30

  Kourilovitch, Maria ^a   Galarza Maldonado, Claudio ^a   Ortiz Prado, Esteban ^b  

^a State University   (Ecuador)

^b UNIVERSIDAD DE LAS AMÉRICAS   (Ecuador)

Author keywords

Anti cyclic citrullinated peptide (anti CCP); Classification criteria; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

ACUTE PHASE PROTEIN; ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOUBLE STRANDED DNA ANTIBODY; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 6 ANTIBODY; PHOSPHOTRANSFERASE INHIBITOR; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTHRALGIA; ARTICLE; CLINICAL FEATURE; COMORBIDITY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; ERYTHROCYTE SEDIMENTATION RATE; HEREDITY; HUMAN; HUMORAL IMMUNE DEFICIENCY; MENTAL DISEASE; META ANALYSIS (TOPIC); MORNING STIFFNESS; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SEROLOGY; SYNOVITIS;

ANTI-CYCLIC CITRULLINATED PEPTIDE (ANTI-CCP); CLASSIFICATION CRITERIA; RHEUMATOID ARTHRITIS; RHEUMATOID FACTOR;

ARTHRALGIA; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CHRONIC DISEASE; COMORBIDITY; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; INFLAMMATION; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; SYNOVITIS;

EID: 84895885192     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.01.027     Document Type: Article

References (56)

1. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
2. Milanino R. Copper in medicine and personal care: a historical overview 2006, 149-160. Copp. Skin New York Inf. Healthc.
3. Garrod A.B. Atreatise on gout and rheumatic gout (rheumatoid arthritis) 1876, Longmans, Green.
4. Garrod A.B. The nature and treatment of gout and rheumatic gout (rheumatoid arthritis) 1876, Longmans Green, Lond.
5. Joshi V.R. Rheumatology, past, present and future. JAssoc Physicians India 2012, 60:21.
6. Ospelt C., Gay S. Epigenetic epidemiol 2012, 289-305. Springer, Available from:. http://link.springer.com/chapter/10.1007/978-94-007-2495-2_15.
7. Gabriel S.E. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001, 27:269-281.
8. Viatte S., Plant D., Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 2013, 9(3):141-153.
9. Lajas C., Abasolo L., Bellajdel B., Hernández-García C., Carmona L., Vargas E., et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Care Res 2003, 49:64-70.
10. Spector T.D., Hart D.J., Powell R.J. Prevalence of rheumatoid arthritis and rheumatoid factor in women: evidence for a secular decline. Ann Rheum Dis 1993, 52:254-257.
11. Peschken C.A., Esdaile J.M. Rheumatic diseases in North America's indigenous peoples. Semin Arthritis Rheum 1999, 28:368-391.
12. Beighton P., Solomon L., Valkenburg H.A. Rheumatoid arthritis in a rural South African Negro population. Ann Rheum Dis 1975, 34:136-141.
13. Alamanos Y., Drosos A.A. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005, 4:130-136.
14. Abdel-Nasser A.M., Rasker J.J., Vaikenburg H.A. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Semin Arthritis Rheum 1997, 27:123-140.
15. Gonzalez A., Icen M., Kremers H.M., Crowson C.S., Davis J.M., Therneau T.M., et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. JRheumatol 2008, 35:1009-1014.
16. Al-Mutairi N., Al-Farag S., Al-Mutairi A., Al-Shiltawy M. Comorbidities associated with psoriasis: an experience from the Middle East. JDermatol 2010, 37:146-155.
17. Gregersen P.K., Silver J., Winchester R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987, 30:1205-1213.
18. Liao K.P., Alfredsson L., Karlson E.W. Environmental influences on risk for rheumatoid arthritis. Curr Opin Rheumatol 2009, 21:279-283.
19. Edwards C.J., Cooper C. Early environmental factors and rheumatoid arthritis. Clin Exp Immunol 2006, 143:1-5.
20. Van Der Kooij S.M., Le Cessie S., Goekoop-Ruiterman Y.P.M., De Vries-Bouwstra J.K., Van Zeben D., Kerstens P.J.S.M., et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2009, 68:1153-1158.
21. Finckh A., Liang M.H., van Herckenrode C.M., de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Care Res 2006, 55:864-872.
22. Ostendorf B., Scherer A., Modder U., Schneider M. Diagnostic value of magnetic resonance imaging of the forefeet in early rheumatoid arthritis when findings on imaging of the metacarpo- phalangeal joints of the hands remain normal. Arthritis Rheum 2004, 50:2094-2102.
23. de Hair M.J., Lehmann K.A., van de Sande M.G., Maijer K.I., Gerlag D.M., Tak P.P. The clinical picture of rheumatoid arthritis according to the 2010 American College of Rheumatology/European League against Rheumatism criteria: is this still the same disease?. Arthritis Rheum 2012, 64(2):389-393.
24. Colebatch A.N., Edwards C.J., Østergaard M., Van Der Heijde D., Balint P.V., D'Agostino M.-A., et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 2013, 72(6):804-814.
25. Young A., Koduri G., Batley M., Kulinskaya E., Gough A., Norton S., et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology 2007, 46:350-357.
26. Nishimura K., Sugiyama D., Kogata Y., Tsuji G., Nakazawa T., Kawano S., et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007, 146(11):797-808.
27. Yukawa N., Fujii T., Kondo-Ishikawa S., Yoshifuji H., Kawabata D., Nojima T., et al. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study. Arthritis Res Ther 2011, 13:R213.
28. Eriksson C., Engstrand S., Sundqvist K.-G., Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα. Ann Rheum Dis 2005, 64:403-407.
29. Emery P., McInnes I.B., van Vollenhoven R., Kraan M.C. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatol Oxf 2008, 47(4):392-398.
30. Skare T.L., Nisihara R., Barbosa B.B. Anti-CCP in systemic lupus erythematosus patients: a cross sectional study in Brazilian patients. Clin Rheumatol 2013, 32(7):1065-1070.
31. Singh U., Singh S., Singh N.K., Verma P.K., Singh S. Anticyclic citrullinated peptide autoantibodies in systemic lupus erythematosus. Rheumatol Int 2011, 31(6):765-767.
32. Kakumanu P., Sobel E.S., Narain S., Li Y., Akaogi J., Yamasaki Y., et al. Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. JRheumatol 2009, 36(12):2682-2690.
33. Tebo A.E., Jaskowski T., Davis K.W., Whiting A., Clifford B., Zeft A., et al. Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2012, 10(1):29.
34. Kim J.-O., Lee J.-S., Choi J.-Y., Lee K.H., Kim Y.-B., Yoo D.-H., et al. The relationship between peripheral arthritis and anti-cyclic citrullinated peptide antibodies in ankylosing spondylitis. Jt Bone Spine 2013, 80(4):399-401.
35. Candia L., Marquez J., Gonzalez C., Santos A.M., Londoño J., Valle R., et al. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis. JClin Rheumatol 2006, 12(5):226-229.
36. Cho S.B., Lee J.H., Ahn K.J., Bae B.G., Kim T., Park Y.-B., et al. Anti-cyclic citrullinated peptide antibodies and joint involvement in Behçet's disease. Yonsei Med J 2012, 53(4):759-764.
37. Pagnoux C., Seror R., Bérezné A., Rouabhia S., Goulvestre C., Guillevin L. Remittent non-destructive polysynovitis in P-ANCA-positive vasculitis patients with anti-CCP antibodies. Jt Bone Spine 2010, 77(6):604-607.
38. Polimeni M., Feniman D., Skare T.S., Nisihara R.M. Anti-cyclic citrullinated peptide antibodies in scleroderma patients. Clin Rheumatol 2012, 31(5):877-880.
39. Kim S.-M., Park E., Lee J.-H., Lee S.-H., Kim H.-R. The clinical significance of anti-cyclic citrullinated peptide antibody in primary Sjögren syndrome. Rheumatol Int 2012, 32(12):3963-3967.
40. Szodoray P., Hajas A., Kardos L., Dezso B., Soos G., Zold E., et al. Distinct phenotypes in mixed connective tissue disease: subgroups and survival. Lupus 2012, 21(13):1412-1422.
41. Ceri M., Unverdi S., Altay M. Anti-cyclic citrullinated peptides positivity rate in patients with familial Mediterranean fever. Clin Exp Rheumatol 2010, 28(4Suppl.60):S58-S61.
42. Lima I., Oliveira R.C., Atta A., Marchi S., Barbosa L., Reis E., et al. Antibodies to citrullinated peptides in tuberculosis. Clin Rheumatol 2013, 32(5):685-687.
43. Fischer A., Solomon J.J., Du Bois R.M., Deane K.D., Olson A.L., Fernandez-Perez E.R., et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 2012, 106(7):1040-1047.
44. Ahlin E., Elshafei A., Nur M., El Safi S.H., Johan R., Elghazali G. Anti-citrullinated peptide antibodies and rheumatoid factor in Sudanese patients with Leishmania donovani infection. Rev Bras Reumatol 2011, 51(6):579-586.
45. Zavala-Cerna M.G., Fafutis-Morris M., Guillen-Vargas C., Salazar-Paíramo M., Garciía-Cruz D.E., Riebeling C., et al. Anti-cyclic citrullinated peptide antibodies and rheumatoid factor sera titers in leprosy patients from Mexico. Rheumatol Int 2012, 32(11):3531-3536.
46. Riccio A., Postiglione L., La Dogana P. Anti-cyclic citrullinated peptide antibodies in patients affected by HCV-related arthritis. JBiol Regul Homeost Agents 2008, 22(1):57-61.
47. Du Toit R., Whitelaw D., Taljaard J.J., Du Plessis L., Esser M. Lack of specificity of anticyclic citrullinated peptide antibodies in advanced human immunodeficiency virus infection. JRheumatol 2011, 38(6):1055-1060.
48. Wladis E.J., Pappa C., Cavaliere L.F. Anticyclic-citrullinated protein antibodies in the diagnosis of ophthalmic inflammatory disease. Ophthal Plast Reconstr Surg 2011, 27(1):e1-2.
49. Lappin D.F., Apatzidou D., Quirke A.-M., Oliver-Bell J., Butcher J.P., Kinane D.F., et al. Influence of periodontal disease, Porphyromonas gingivalis and cigarette smoking on systemic anti-citrullinated peptide antibody titres. JClin Periodontol 2013, 40(10):907-915.
50. Tasliyurt T., Kisacik B., Kaya S.U., Yildirim B., Pehlivan Y., Kutluturk F., et al. The frequency of antibodies against cyclic citrullinated peptides and rheumatoid factor in healthy population: a field study of rheumatoid arthritis from northern turkey. Rheumatol Int 2013, 33(4):939-942.
51. Gullick N.J., Scott D.L. Co-morbidities in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2011, 25(4):469-483.
52. Quinn M.A., Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003 Sep-Oct, 21(5 Suppl.31):S154-S157.
53. Smolen J.S., Aletaha D., Bijlsma J.W.J., Breedveld F.C., Boumpas D., Burmester G., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010 Apr, 69(4):631-637.
54. Zeidler H. Systemic literature review of the performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: good news of debatable significance. Ann Rheum Dis 2013, 72:e21.
55. Caporali R., Bugatti S., Cavagna L., Antivalle M., Sarzi-Puttini P. Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment?. Autoimmun Rev 2014, 13:49-53.
56. Boissier M.C., Semerano L., Challal S., Saidenberg-Kermanac'h N., Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. JAutoimmun 2012, 39:222-228.